Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Bank of America Corp DE

Bank of America Corp DE increased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 218.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 556,881 shares of the company's stock after purchasing an additional 382,222 shares during the quarter. Bank of America Corp DE owned 0.18% of Amneal Pharmaceuticals worth $4,410,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in AMRX. BNP Paribas Financial Markets increased its position in shares of Amneal Pharmaceuticals by 209.2% during the fourth quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock valued at $1,332,000 after buying an additional 113,796 shares during the period. Voleon Capital Management LP purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at about $443,000. PDT Partners LLC purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at about $627,000. Nantahala Capital Management LLC increased its position in shares of Amneal Pharmaceuticals by 37.3% during the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock valued at $29,031,000 after buying an additional 995,586 shares during the period. Finally, Northern Trust Corp increased its position in shares of Amneal Pharmaceuticals by 9.7% during the fourth quarter. Northern Trust Corp now owns 1,777,283 shares of the company's stock valued at $14,076,000 after buying an additional 156,699 shares during the period. Hedge funds and other institutional investors own 31.82% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd. Wall Street Zen lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Finally, JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $11.50.

Insider Activity

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This trade represents a 9.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Stock Up 1.4%

Amneal Pharmaceuticals stock traded up $0.10 during midday trading on Monday, reaching $7.42. The stock had a trading volume of 1,645,302 shares, compared to its average volume of 1,442,672. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.29 and a 52-week high of $9.48. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -10.91 and a beta of 1.17. The company has a fifty day moving average of $7.46 and a 200 day moving average of $7.98.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.05. The company had revenue of $695.42 million during the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.